Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin) Followed by Capecitabine (Xeloda) Plus Radiotherapy (RTx)

NCT01434147 is registered in ClinicalTrials.gov with Austrian Breast & Colorectal Cancer Study Group as lead sponsor.

NCT NCT01434147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01434147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin) Followed by Capecitabine (Xeloda) Plus Radiotherapy (RTx)
Lead sponsor
Austrian Breast & Colorectal Cancer Study Group
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
August 31, 2013
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer